John Paganelli - Opko Health Independent Director
| OPK Stock | USD 1.23 0.02 1.60% |
Director
Mr. John A. Paganelli serves as Independent Director of the Company. Mr. Paganelli has served as a director of the Company since December 2003. Mr. Paganelli served as the Companys Interim Chief Executive Officer and Secretary from June 29, 2005 through March 27, 2007, the Companys Interim Chief Financial Officer from June 29, 2005 through July 1, 2005, and Chairman of our Board from December 2003 through March 27, 2007. Mr. Paganelli served as President and Chief Executive Officer of Transamerica Life Insurance Company of New York from 1992 to 1997. Since 1987, Mr. Paganelli was a partner in RFG Associates, a financial planning organization. Mr. Paganelli is also the Managing Partner of Pharos Systems Partners, LLC, an investment company, and he is Chairman of the Board of Pharos Systems International, a software company. He was Vice President and Executive Vice President of PEG Capital Management, an investment advisory organization, from 1987 until 2000 since 2007.
| Age | 83 |
| Tenure | 17 years |
| Address | 4400 Biscayne Boulevard, Miami, FL, United States, 33137 |
| Phone | 305 575 4100 |
| Web | https://www.opko.com |
Opko Health Management Efficiency
The company has Return on Asset of (0.0473) % which means that on every $100 spent on assets, it lost $0.0473. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.128) %, meaning that it generated no profit with money invested by stockholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.41. The value of Return On Capital Employed is expected to slide to -0.09. At this time, Opko Health's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to 0.00 this year, although the value of Total Current Liabilities will most likely fall to about 103.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mai Xiaoying | Twist Bioscience Corp | 30 | |
| R Keith | Thermo Fisher Scientific | 52 | |
| Sue Rataj | Agilent Technologies | 63 | |
| Stanley Meresman | Guardant Health | 71 | |
| Daniel Podolsky | Agilent Technologies | 67 | |
| William Parrett | Thermo Fisher Scientific | 71 | |
| Arthur Bowman | Illumina | 69 | |
| Laurie Glimcher | Waters | 66 | |
| Robert Herbold | Agilent Technologies | 74 | |
| Susan Siegel | Illumina | 57 | |
| Dipchand Nishar | Guardant Health | N/A | |
| Sperling Sperling | Thermo Fisher Scientific | 58 | |
| Gary Hendrickson | Waters | 64 | |
| Judy Lewent | Thermo Fisher Scientific | 71 | |
| William Miller | Waters | 70 | |
| Francis deSouza | Illumina | 53 | |
| Daniel Bradbury | Illumina | 56 | |
| Robert Ragusa | Twist Bioscience Corp | 58 | |
| Philip Schiller | Illumina | 57 | |
| Heidi Kunz | Agilent Technologies | 66 | |
| Ian Clark | Guardant Health | 57 | |
Management Performance
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0473 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arie Gutman, Pres API | ||
| Dr MBA, Vice Officer | ||
| FACP FASN, Senior Renal | ||
| David Okrongly, President Diagnostics | ||
| Antonio Cruz, President Therapeutics | ||
| Dmitry Kolosov, Independent Director | ||
| Richard Lerner, Independent Director | ||
| Thomas Nusbickel, Chief Commercial Officer of the Company's Renal Division | ||
| Elias MD, President Chairman | ||
| Richard Pfenniger, Independent Director | ||
| Philip Frost, Chairman of the Board, CEO | ||
| Thomas Beier, Director | ||
| Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
| Jon Cohen, Executive Chairman of BioReference Laboratories | ||
| Robert Fishel, Independent Director | ||
| Robert Baron, Independent Director | ||
| Anne Fields, IR Contact Officer | ||
| Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
| Alice Yu, Independent Director | ||
| Steven Rubin, Executive Vice President - Administration, Director | ||
| JD Esq, Chief Laboratories | ||
| Charles Bishop, Chief Renal | ||
| Hans Berner, President Iberoamerica | ||
| James DeMarco, VP Sales | ||
| John Paganelli, Independent Director | ||
| Phillip Frost, Chairman of the Board, CEO | ||
| Miriam Miller, IR Contact Officer | ||
| MBA MBA, Vice Officer | ||
| Jon MD, Advisor | ||
| Jane Hsiao, Vice Chairman of the Board, Chief Technical Officer | ||
| Geoff Monk, President of BioReference | ||
| Richard Krasno, Independent Director |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0473 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.38) % | ||||
| Current Valuation | 1.07 B | ||||
| Shares Outstanding | 696.99 M | ||||
| Shares Owned By Insiders | 52.40 % | ||||
| Shares Owned By Institutions | 25.06 % | ||||
| Number Of Shares Shorted | 93.61 M | ||||
| Price To Earning | 7.46 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Opko Stock please use our How to buy in Opko Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Opko Stock analysis
When running Opko Health's price analysis, check to measure Opko Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opko Health is operating at the current time. Most of Opko Health's value examination focuses on studying past and present price action to predict the probability of Opko Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opko Health's price. Additionally, you may evaluate how the addition of Opko Health to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Opko Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opko Health. If investors know Opko will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opko Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.191 | Earnings Share (0.25) | Revenue Per Share 1.149 | Quarterly Revenue Growth (0.02) | Return On Assets (0.05) |
The market value of Opko Health is measured differently than its book value, which is the value of Opko that is recorded on the company's balance sheet. Investors also form their own opinion of Opko Health's value that differs from its market value or its book value, called intrinsic value, which is Opko Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opko Health's market value can be influenced by many factors that don't directly affect Opko Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opko Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Opko Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opko Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.